Ziwen Wei

7.1k total citations
18 papers, 416 citations indexed

About

Ziwen Wei is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Ziwen Wei has authored 18 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Hepatology and 4 papers in Epidemiology. Recurrent topics in Ziwen Wei's work include Cancer Immunotherapy and Biomarkers (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Advanced Radiotherapy Techniques (3 papers). Ziwen Wei is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (5 papers) and Advanced Radiotherapy Techniques (3 papers). Ziwen Wei collaborates with scholars based in United States, China and France. Ziwen Wei's co-authors include F. Stephen Hodi, Anna C. Pavlick, Caroline Robert, Adil Daud, Dirk Schadendorf, April K.S. Salama, Tara C. Gangadhar, Kim Margolin, Jacob Schachter and Paolo A. Ascierto and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Ziwen Wei

16 papers receiving 408 citations

Peers

Ziwen Wei

ONCOL

PRM

IMMUN

HEPAT

Yulin Tan China

Nikoletta Sidiropoulos United States

Depei Huang China

Deirdre Kelly Canada

Lihou Dong China

Marco Brugia Italy

Shotaro Kato Japan

Fucun Xie China

Laura Demurtas Italy

Francesca Comito Italy

Yulin Tan China

Ziwen Wei

162 ×0.5

ONCOL

139 ×1.1

PRM

94 ×1.0

111 ×1.6

IMMUN

47 ×1.0

HEPAT

Citations per year, relative to Ziwen Wei Ziwen Wei (= 1×) peers Yulin Tan

Countries citing papers authored by Ziwen Wei

Since Specialization

Citations

This map shows the geographic impact of Ziwen Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ziwen Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ziwen Wei more than expected).

Fields of papers citing papers by Ziwen Wei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ziwen Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ziwen Wei. The network helps show where Ziwen Wei may publish in the future.

Co-authorship network of co-authors of Ziwen Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Ziwen Wei. A scholar is included among the top collaborators of Ziwen Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ziwen Wei. Ziwen Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wei, Ziwen, et al.. (2025). Lymph node-targeted delivery of cancer vaccine with natural plant derivatives potentiates antitumor efficacy through improved antigen presentation. Chemical Engineering Journal. 522. 167320–167320.

Wei, Ziwen, Xiaolong Wu, Qi Wang, et al.. (2025). RSME: Respiration-Driven Synchronized Motion Estimator for Real-Time Thoracic 3-D CT Reconstruction Using Low-Rank Motion Fields and Dose-Free Surface Imaging. IEEE Transactions on Neural Networks and Learning Systems. 36(9). 16879–16893.

Xu, Haidong, Xianbao Sun, Zheng Huang, et al.. (2025). Displaying In Vivo “Assembly–Disassembly” Cascade with “Off–On–Off” Magnetic Resonance Imaging Signals in Tumor. Journal of the American Chemical Society. 147(27). 23923–23930. 6 indexed citations

Wei, Ziwen, et al.. (2024). Feasibility evaluation of radiotherapy positioning system guided by augmented reality and point cloud registration. Journal of Applied Clinical Medical Physics. 25(4). e14243–e14243. 2 indexed citations

Wei, Ziwen, Huang Xiang, Aiming Sun, et al.. (2024). A model that predicts a real-time tumour surface using intra-treatment skin surface and end-of-expiration and end-of-inhalation planning CT images. British Journal of Radiology. 97(1157). 980–992. 1 indexed citations

Merle, Philippe, Masatoshi Kudo, Julien Edeline, et al.. (2023). Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial. Liver Cancer. 12(4). 309–320. 31 indexed citations

Wei, Ziwen, et al.. (2023). Research on the Current Situation and Future Development Trend of Immersive Virtual Reality in the Field of Education. Sustainability. 15(9). 7531–7531. 17 indexed citations

Finn, Richard S., Julien Edeline, Mohamed Bouattour, et al.. (2021). Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.. Journal of Clinical Oncology. 39(15_suppl). 4072–4072. 3 indexed citations

Merle, Philippe, Julien Edeline, Mohamed Bouattour, et al.. (2021). Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase III KEYNOTE-240 study.. Journal of Clinical Oncology. 39(3_suppl). 268–268. 14 indexed citations

10.

Vogel, Arndt, Philippe Merle, Chris Verslype, et al.. (2021). ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Therapeutic Advances in Medical Oncology. 13. 4277451960–4277451960. 12 indexed citations

11.

Garassino, Marina Chiara, Shirish M. Gadgeel, Emilio Esteban, et al.. (2020). Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology. 21(3). 387–397. 138 indexed citations

12.

Wei, Ziwen, et al.. (2020). MiR-142-3p inhibits adipogenic differentiation and autophagy in obesity through targeting KLF9. Molecular and Cellular Endocrinology. 518. 111028–111028. 12 indexed citations

13.

Gray, Jhanelle E., Taofeek K. Owonikoko, Terufumi Kato, et al.. (2020). 1418TiP Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance olaparib in patients (Pts) with metastatic squamous non-small cell lung cancer (sqNSCLC): KEYLYNK-008. Annals of Oncology. 31. S896–S896. 5 indexed citations

14.

Vogel, Arndt, Philippe Merle, Chris Verslype, et al.. (2020). 1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240. Annals of Oncology. 31. S696–S697. 1 indexed citations

15.

Hamid, Omid, Igor Puzanov, Reinhard Dummer, et al.. (2017). Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer. 86. 37–45. 135 indexed citations

16.

Gantz, Ira, Л.К. Соколова, Lokesh Jain, et al.. (2017). Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds. Clinical Therapeutics. 39(10). 2024–2037. 5 indexed citations

17.

Handelsman, Yehuda, Brett Lauring, Ira Gantz, et al.. (2017). A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current Medical Research and Opinion. 33(10). 1861–1868. 13 indexed citations

18.

Hamid, Omid, Igor Puzanov, Reinhard Dummer, et al.. (2016). Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma. Annals of Oncology. 27. vi379–vi379. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact